Vivacelle Bio Inc SBIR Phase II award

Department of Health and Human Services, through National Institutes of Health, awarded Vivacelle Bio Inc of Kansas City, MO $690,878 under the SBIR program (Phase II), with work starting 2026-09-15 and running to 2028-08-31. It is one of 2 SBIR and STTR awards Vivacelle Bio Inc received in the last two years, $1,004,784 in all. Each figure links to the federal record.

The award

Want the whole picture on Vivacelle Bio Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Vivacelle Bio Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vivacelle Bio Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What it is for

Development of a phospholipid nanoparticle and small molecule-based combination drug for the treatment of lethal sepsis - project summary sepsis is a life-threatening organ dysfunction caused by a dysregulated host respo

Funding actions on this award

Development of a phospholipid nanoparticle and small molecule-based combination drug for the treatment of lethal sepsis - project summary sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection. An estimated 1.7 million adults are affected by sepsis, and 350,000 among them succumb to IT every year in the US alone. Currently, there are no fda-approved drugs for treating sepsis since previous clinical trials proved unsuccessful. Conventional antibiotic treatment is still one of the mainstays in the management of sepsis, and a large number of resources are being pumped into the development of new antibiotics. However, the ever- increasing antibiotic resistance of bacteria poses serious concerns. Hence, there is a critical unmet need for a treatment of sepsis that does not rely on the use of antibiotics. To this end, vivacelle bio inc (vbi) is developing vbi-optimum (vbi-o), an innovative combination of a phospholipid nanoparticle colloid (pnc) with ETHYL-3- hydroxybutyrate (ehb), to treat septic shock by modulating macrophage function and inflammatory signaling. Physicians will be able to prescribe vbi-o, and the administration of the drug will be via a simple injection into the abdominal cavity along with antibiotics as opposed to intravenous antibiotics alone. In this SBIR Phase II, vbi will further develop and validate the optimum c ...

From the federal award record.

Other SBIR and STTR awards to Vivacelle Bio Inc

Where this comes from

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.

Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.

All SBIR and STTR awards